TGen's Cancer Drug Discovery Laboratory Relocates to Mayo Clinic 
Collaborative Research Building


Move enhances multidisciplinary environment, accelerates research

06-30-2005

Phoenix, AZ, June 30, 2005 -- The Translational Genomics Research 
Institute (TGen) today announced the transition of its Cancer Drug 
Discovery Laboratory (CDDL) from their Gaithersburg, MD, facility to 
the new Mayo Clinic Collaborative Research Building on the 
Scottsdale campus of the Mayo Clinic. The CDDL was established as 
TGen's drug discovery and development arm. 
Co-locating CDDL and TGen's Drug Development (TD2) Services Unit 
with researchers at the Mayo Clinic is a key component of TGen's 
patient-centered research approach. The combination of world-class 
researchers and the latest technologies creates a highly 
collaborative multidisciplinary research environment, ensuring that 
innovative preclinical research products will be moved from the lab 
to the patient as quickly as possible. This will hopefully 
ultimately improve and extend the lives of patients living with 
cancer. 

"The TGen-Mayo Clinic collaboration signifies a milestone, both in 
terms of Arizona's leadership in bringing the best that biomedicine 
has to offer to patients nationally and internationally and the 
potential that research results between these two institutions will 
have toward defeating cancer," said Sen. John McCain. 

CDDL investigators are a multi-disciplinary team of scientists with 
expertise ranging from cell biology to bioinformatics. The lab uses 
a powerful cutting-edge technology called RNA interference (RNAi) 
technology to accelerate their research. The area of RNAi opens up a 
new field for drug discovery and will allow researchers to develop 
specific and potent drugs. RNAi technology centers on understanding 
how genes are turned on and off in cells and what the effect is on 
those cells. 

"The CDDL team has assembled some of the most sophisticated and high-
throughput technology in the world for studying cancer cells," said 
Dr. Spyro Mousses, Director of CDDL. "Our RNAi technology should 
greatly accelerate the discovery of new anti-cancer compounds." 

The move to the Mayo Clinic Collaborative Research Building will 
nearly triple CDDL's current capacity. The new building, which 
officially opens its doors today, is an 110,000-square-foot facility 
specifically devoted to developing and supporting medical research 
that will help patients in Arizona and beyond. 

"The CDDL's proximity to our researchers and clinicians accelerates 
our joint pursuit of identifying strategies to defeat all forms of 
cancer and further strengthens the Mayo Clinic mission of 
integrating research and educational efforts with clinical medicine 
to provide the best care for our patients," said Victor F. Trastek, 
MD, Chair, Board of Governors at Mayo Clinic. 

Mousses and his team are settling into the lab over the next few 
months and will be completely moved in by early next year. 

"CDDL's move to Arizona strengthens TGen's attack on cancer. The 
addition of these researchers not only bolsters the translational 
arm of TGen's discovery work, but proves that good science is 
happening right here in Arizona, and with it comes the hope of 
finding new ways to stop cancer in its tracks," said Dr. Jeffrey 
Trent, TGen's President and Scientific Director. 

# # # 

About TGen
The mission of the Translational Genomics Research Institute (TGen) 
is to make and translate genomic discoveries into advances in human 
health. Translational genomics research is a relatively new field 
employing innovative advances arising from the Human Genome Project 
and applying them to the development of diagnostics, prognostics and 
therapies for cancer, neurological disorders, diabetes and other 
complex diseases. TGen is focused on personalized medicine and plans 
to accomplish its goals through robust and disease-focused research 
programs and its state-of-the-art bioinformatics and computational 
biology facilities. 

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/";>Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/";>Biotech 
News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/";>Arizona 
Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/";>Arizona High Tech</a>







http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/";>Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/";>Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/";>Arizona High Tech</a>
 
Yahoo! Groups Links

<*> To visit your group on the web, go to:
    http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
    [EMAIL PROTECTED]

<*> Your use of Yahoo! Groups is subject to:
    http://docs.yahoo.com/info/terms/
 


Reply via email to